

FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: Aion Therapeutic Inc. (the “Issuer”).

Trading Symbol: AION

SCHEDULE A: FINANCIAL STATEMENTS

The condensed interim consolidated financial statements for the nine months ended January 31, 2021 and 2020 are attached as Schedule “A”.

SCHEDULE B: SUPPLEMENTARY INFORMATION

1. Related party transactions

See Note 11 of Schedule “A”.

2. Summary of securities issued and options granted during the period.

See Note 10 of Schedule “A”.

3. Summary of securities as at the end of the reporting period.

See Note 10 of Schedule “A”.

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Dr. Stephen Barnhill – Director and Executive Chair
Graham Simmonds – Director, CEO and Executive Vice Chair
Paul Crath – Director and Lead Independent Director
Larry Horwitz – Director
Rosy Mondin – Director
Sara Lee Irwin – Director
Dr. Anthony Hall – Director
Rakesh Malhotra - CFO

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Management’s discussion and analysis for the nine months ended January 31, 2021 are attached as Schedule “C”.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated April 1, 2021.

Graham Simmonds
Name of Director or Senior Officer

(Graham Simmonds) "signed"
Signature

CEO
Official Capacity

Issuer Details Name of Issuer Aion Therapeutic Inc.	For Quarter Ended January 31, 2021	Date of Report YY/MM/DD 21/04/01
Issuer Address 45 Sheppard Avenue East, Suite 703		
City/Province/Postal Code Toronto, Ontario, M2N 5W9	Issuer Fax No. N/A	Issuer Telephone No. (416) 843-2881
Contact Name Graham Simmonds	Contact Position CEO	Contact Telephone No. (416) 843-2881
Contact Email Address graham.simmonds@aiontherapeutic.com	Web Site Address www.aiontherapeutic.com	

SCHEDULE "A"

SCHEDULE “C”